Penpulimab-kcqx: FDA-Approved PD-1 Inhibitor for non-keratinizing Nasopharyngeal Carcinoma
Name of Drug : Penpulimab-kcqx Drug Category : Antineoplastic agent Form : Injection . Introduction : Nasopharyngeal carcinoma (NPC) is a rare cancer that arises in the nasopharynx, most often seen in the non-keratinizing form linked to the Epstein Barr virus. In April 2025, the FDA approved a promising immunotherapy: penpulimab KCQX, a next-generation PD1 …